en Pediatric Hematology & Oncology Pediatric Hematology & Oncology پژوهشي Original Article <div style="BORDER-BOTTOM: black 1pt solid BORDER-LEFT: medium none PADDING-BOTTOM: 1pt PADDING-LEFT: 0cm PADDING-RIGHT: 0cm BORDER-TOP: medium none BORDER-RIGHT: medium none PADDING-TOP: 0cm mso-element: para-border-div mso-border-bottom-alt: solid black .75pt"><p style="MARGIN: 0cm 0cm 3pt" class="IJBC-AbstractBody"><font size="2"><font face="Calibri"><b><span style="mso-ansi-language: EN-GB" lang="EN-GB">Background: </span></b><span style="mso-ansi-language: EN-GB" lang="EN-GB">Medulloblastoma is the most common malignant brain tumor in children. The important factors in predicting survival are the extent of disease, proliferation index of the tumor cells, histopathologic class and the age at diagnosis. The percentage of Ki-67 positive cells reflects the proliferation<span style="mso-spacerun: yes">  </span>of the cells and is one of the critical factors which determine the growth of the tumor. Monoclonal MIB-1 antibody can be targeted against recombinant Ki-67 and then demonstrated by immunohistochemical methods.<b> </b></span></font></font><p></p><p style="MARGIN: 0cm 0cm 3pt" class="IJBC-AbstractBody"><font size="2"><font face="Calibri"><b><span style="mso-ansi-language: EN-GB" lang="EN-GB">Materials and Methods: </span></b><span style="mso-ansi-language: EN-GB" lang="EN-GB">Formalin-fixed, paraffin-embedded tissue of 18 pediatric patients with medulloblastoma at <p lace w:st="on" ><p lacename w:st="on" >Mofid</placename /> <p lacename w:st="on" >Children</placename /> <p lacetype w:st="on" >Hospital</placetype /></place /> between January 2003 and December 2008 were used to perform Ki-67 (MIB-1) immunohistochemical analysis. Proliferative labeling index (LI ) was scored in the tumor cells to determine the extent of proliferation. </span></font></font><p></p><p style="MARGIN: 0cm 0cm 3pt" class="IJBC-AbstractBody"><font size="2"><font face="Calibri"><b><span style="mso-ansi-language: EN-GB" lang="EN-GB">Results: </span></b><span style="mso-ansi-language: EN-GB" lang="EN-GB">The mean±SD of MIB-1 LI index was 53%±21% (range 25% to 85%). Kaplan–Meier curves showed that patients with MIB-1 LI <40% had higher 5-year survival than patients with MIB-1 LI> 40%<span style="mso-spacerun: yes">  </span>(<i>p</i>=0.04). This difference remained statistically significant in Cox regression analysis. </span></font></font><p></p><p style="MARGIN: 0cm 0cm 3pt" class="IJBC-AbstractBody"><font size="2"><font face="Calibri"><b><span style="mso-ansi-language: EN-GB" lang="EN-GB">Conclusion: </span></b><span style="mso-ansi-language: EN-GB" lang="EN-GB">We suggest that MIB-1 LI is helpful as a prognostic factor in predicting survival of patients with pediatric medulloblastoma.</span></font></font><p></p></p><p></p></p><p></p></p><p></p></p><p></p></div> Meduloblastoma, MIB-1, Prognosis 7 10 http://ijbc.ir/browse.php?a_code=A-10-2-162&slc_lang=en&sid=1